750 related articles for article (PubMed ID: 21156233)
1. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
Sun Y; Cook JR
Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
[TBL] [Abstract][Full Text] [Related]
7. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
9. Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5.
Douet-Guilbert N; Basinko A; Eveillard JR; Morel F; Le Bris MJ; Guéganic N; Bovo C; Herry A; Berthou C; De Braekeleer M
Cancer Genet Cytogenet; 2010 Dec; 203(2):303-8. PubMed ID: 21156249
[TBL] [Abstract][Full Text] [Related]
10. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
Yilmaz Z; Sahin FI; Kizilkilic E; Karakus S; Boga C; Ozdogu H
Clin Exp Med; 2005 Jul; 5(2):55-9. PubMed ID: 16096854
[TBL] [Abstract][Full Text] [Related]
11. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
[TBL] [Abstract][Full Text] [Related]
12. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
[TBL] [Abstract][Full Text] [Related]
14. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
15. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
[TBL] [Abstract][Full Text] [Related]
16. Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report.
Znoyko I; Stuart RK; Ellingham T; Winters J; Wolff DJ; Quigley DI
Cancer Genet Cytogenet; 2008 May; 183(1):64-8. PubMed ID: 18474300
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
18. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization].
Shen Y; Xue Y; Li J; Pan J; Wu Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):160-3. PubMed ID: 12673589
[TBL] [Abstract][Full Text] [Related]
19. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
20. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
